A type of mouth bacteria involved in gum disease is able to infect human brain cells, new research shows. The infection results in cellular changes that are similar to what is seen in Alzheimer’s, supporting a link between the bacteria and the neurodegenerative disease. The findings were presented at the Advances in Alzheimer’s and Parkinson’s…
The U.S. Food and Drug Administration (FDA) has approved Tauvid (flortaucipir F18) as an imaging radiotracer agent — a radioactive diagnostic tool — to efficiently detect clumps of tau protein in the brain, one of the hallmarks of Alzheimer’s disease. “Alzheimer’s disease is a devastating condition that affects millions of Americans. This approval will provide health…
Cassava Sciences‘s investigational therapy PTI-125 failed to significantly lower the levels of Alzheimer’s-relevant biomarkers present in fluid surrounding the brain and spinal cord of patients, according to results from a Phase 2b clinical trial. The company announced it will study these topline data in deciding next steps for PTI-125 as a potential treatment. Alzheimer’s disease…
Axsome Therapeutics‘ investigational oral therapy AXS-05 significantly and rapidly lessened agitation in patients with Alzheimer’s disease, top-line results from a Phase 2/3 trial show. The therapy was also found to be generally well-tolerated and safe, without affecting cognition. “I am very pleased to see the promising results of the ADVANCE-1 trial, providing clear evidence of reduced agitation…
Taking daily low-dose aspirin does not seem to reduce the risk of dementia, cognitive decline, or Alzheimer’s disease, new clinical trial data show. The results were published in Neurology in a study, titled “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.” Aspirin is a widely-used anti-inflammatory medication. Among its uses, low-dose daily…
FFF Enterprises and BioNews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of critical-care biopharmaceuticals, plasma products and…
A wise man once said, “No one by worrying can add one inch to their height.” Constantly worrying about acquiring an admittedly horrible disease may be useless, but it also is common practice for caregivers. Our intimate involvement in the daily processes of a disease, and seeing how it affects our loved ones affects us,…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that we would learn how valuable…
Biogen is pushing back the submission of aducanumab, its investigational treatment for Alzheimer’s disease, to the U.S. Food and Drug Administration (FDA) to the third quarter of this year due to the COVID-19 pandemic, the company announced. “The COVID-19 pandemic has created a challenging situation for people and companies throughout the world, and Biogen personally…
It helps to have something on the back burner, something to anticipate in the days, weeks, and months ahead. We need something on which to place our concentration, other than COVID-19. Summer solstice is that thing. Not the day so much, but the annual event surrounding it. Alzheimer’s Association Continues ‘Longest Day’ Since 2012, the…
